Compare Avantis US Small Cap Value ETF (AVUV) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs Bristol-Myers Squibb Co — how do they compare? Avantis US Small Cap Value ETF trades at $127.37, while Bristol-Myers Squibb Co trades at $63.72 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Avantis US Small Cap Value ETF pays none. Which is the better fit depends on your goals.
| AVUV | BMY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $128.74 | $65.89 |
52-Week Low | $93.93 | $42.60 |
Market Cap | — | $129.94B |
Enterprise Value | — | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVUV trades at $127.03, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bullish trend with moving averages strongly supporting upside momentum while oscillators remain neutral. The ETF has attracted significant attention for its small-cap value exposure, with recent articles highlighting its strong performance relative to broader small-cap indices and its role in diversifying tech-heavy portfolios.
Outlook remains positive as small-cap value continues outperforming growth stocks in 2026. Investment opportunity lies in continued rate cut expectations and regional bank exposure driving returns. Key risks include sensitivity to interest rate changes, higher volatility typical of small-caps, and concentrated US market exposure limiting global diversification benefits.
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
